Smith+Nephew plans buyback and keeps annual outlook
Smith+Nephew reported a 3.1% rise in quarterly revenue driven by sports medicine growth. The firm kept its annual outlook and set a 500 million dollar buyback.
SMITH & NEPHEW PLC grew underlying revenue 3.1% in the first quarter and launched a $500 million share buyback. The medical device maker maintained its full-year financial guidance following growth in its sports medicine and wound management divisions. The buyback and steady outlook signal management confidence despite broader sector volatility in the United Kingdom.
### Sports Medicine and Wound Care Drive Growth The revenue increase stemmed from strong demand in specialized surgical and recovery segments. Smith & Nephew reported that sports medicine and advanced wound management outperformed other business units during the period. These results align with the company's multi-year plan to improve operational margins.
